Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
| Brand name | METFORMIN HYDROCHLORIDE EXTENDED RELEASE |
| Generic name | METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE |
| Distributed by / for | Time-Cap Labs, Inc. 7 Michael Avenue Farmingdale, NY 11735, USA |
| NDC | 49483-623-09 |
| Full product label | Time-Cap Labs, Inc. Metformin Hydrochloride Extended-Release Tablets USP 500 mg, a) 90 count (NDC 49483-623-09) b) 100 count (49483-623-01) c) 500 count (NDC 49483-623-50) and d) 1000 count (NDC 49483-623-10) bottles, Rx Only Manufactured for: Time-Cap Labs, Inc. 7 Michael Avenue Farmingdale, NY 11735, USA, Manufactured by: Marksans Pharma Ltd. Plot No. L-82, L-83, Verna Indl. Estate. Verna Goa-403 722 India NDC 49483-623-50 |
| Recalling firm | Marksans Pharma Limited |
| Distribution | Nationwide |
| Quantity | a) 64,590 b) 23,834 c) 109,125 d) 27839 bottles |
| Recall initiated | 2020-10-02 |
| Report date | 2020-11-11 |
| Recall completed | 2024-02-21 |
| Recall number | D-0061-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Vasco Da Gama N/A India |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗